

Research Article

Assessment of the Levels of TGF- β 1 and IL-18 in Gastritis Patients Infected with *Helicobacter pylori*

Ahoodabd Alhussen Habeeb¹, Halah Abdulkhaliq Awadh², Firas Fairs Rija³

¹Salah Al-Din Health Department, Balad General Hospital.

^{2,3}Department of Biology, College of Sciences, Tikrit University, Tikrit.

DOI: <https://doi.org/10.24321/0019.5138.202414>

I N F O

Corresponding Author:

Ahoodabd Alhussen Habeeb, Salah Al-Din Health Department, Balad General Hospital.

E-mail Id:

ahoodalrubaye@gmail.com

Orcid Id:

<https://orcid.org/0000-0003-2318-8950>

How to cite this article:

Habeeb A A, Awad H A K, Raja F F. Assessment of the Levels of TGF- β 1 and IL-18 in Gastritis Patients Infected with *Helicobacter pylori*. J Commun Dis. 2024;56(1):99-105.

Date of Submission: 2023-08-30

Date of Acceptance: 2023-09-23

A B S T R A C T

Background: Gastritis is characterised as an inflammation of the gastric mucosa, the stomach's protective lining, and is divided into two categories: acute and chronic, depending on the severity of the inflammation and the disease's history. This study aims to estimate the levels of transforming growth factor-beta 1 (TGF- β 1) and interleukin-18 (IL-18) in gastritis patients infected with *Helicobacter pylori*.

Material and Method: From September 2022 to June 2023, a cross-sectional study was conducted in the General Hospital and at various private clinics in Balad City, Iraq. Eighty-nine samples (50 patients and 39 healthy individuals as control) were collected from 42 males and 47 females aged 15–85 years from Balad General Hospital, and private upper surgical endoscopy clinic. Blood, stool, and biopsy samples were collected from individuals suffering from complaints such as loss of appetite, weight loss, diarrhoea, vomiting, and dyspepsia.

Results: The study included 89 samples (50 gastritis patients (56.18%) and 39 control (43.82%)). Depending on the diagnosis of gastroenterologists, the gastric patients were divided into four groups: 28 (56%) were gastritis patients, 13 (26%) patients were chronic gastritis patients, 8 (16%) patients were gastritis ulcer patients, and 1 (2%) patient was gastric cancer patient. *H. pylori* was detected by antibody (Ab) and antigen (Ag) in the serum among all 50 patients using the one step test. Among the 50 patients, 26 (52%) showed a positive result for Ab and 24 (48%) showed a negative result, while 20 (40%) were positive and 30 (60%) were negative for Ag. In addition, this research found that the concentration of TGF- β 1 and IL-18 in *H. pylori*-infected patients was significantly ($p \leq 0.05$) higher than that in healthy controls.

Conclusion: IL-18 and TGF- β 1 levels were elevated in the serum of people with gastritis *H. pylori* infection in this study as compared to the healthy groups. A correlation was found between TGF- β 1 and IL-18 serum levels in relation to *H. pylori* and bacterial infection.

Keywords: TGF- β 1, IL-18, *H. pylori*, Gastritis

Introduction

Gastritis is an inflammation of the gastric mucosa, the stomach's protective lining, and is divided into two categories: acute and chronic, depending on the severity of the inflammation and the disease's history.¹ *Helicobacter pylori* is a human-to-human-transmitted gram-negative microaerophilic bacteria that causes gastroenteritis, ulcers of the stomach, mucosa-associated lymphoid tissue lymphoma and gastric cancer.² *H. pylori* has been identified as a group 1 carcinogenic pathogen since 1994,³ according to the International Agency for Research on Cancer. Inhibiting B- and T-lymphocyte proliferation and decreasing macrophage and natural killer cell activity, transforming growth factor-1 (TGF-1) has a crucial function in regulating inflammatory responses.⁴ In addition to its role as a regulator of cytokine production by various cell types, TGF-1 also operates as a chemoattractant and activator of monocyte activities.⁵ Major autoimmune responses are also seen by developing stomach dysplastic lesions and severe gastric inflammation and ulceration. Mutations in the gastric mucosa of TGF-1 null mice are strikingly comparable to those of *H. pylori*-associated gastritis. The 192 and 193 amino acids that make up human interleukin-18 (IL-18) proteins have been determined.⁶ IL-18 is categorised as an IL-1 cytokine due to the similarity between its amino acid sequence and that of IL-1. Despite sharing a β -sheet structure,⁷ the sole sequence homology between human IL-18 and IL-1 is 15%. The purpose of this research was to estimate the levels of TGF- β 1 and IL-18 in gastritis patients infected with *H. pylori*.

Material and Method

This cross-sectional study was conducted between September 2022 and June 2023 at the Balad General Hospital and private upper surgical endoscopy clinic in Balad City, Iraq. A total of 89 samples were taken (42 men and 47 women) spanning 15–85 years of age (50 patients and 39 healthy persons as controls). Blood, stool, and biopsy samples were collected from individuals suffering

from complaints such as loss of appetite, weight loss, diarrhoea, vomiting, and dyspepsia. Blood samples were collected using disposable syringes; 3–5 mL of venous blood was collected from each person's vein. After transferring the blood to gel tubes, it was left to coagulate at room temperature and spun at 1,500 RPM for 15 minutes. The sera were stored at -20°C until further analyses were performed.⁸ A questionnaire was prepared and designed according to the criteria that included study information (age - sex -Pathological case)

Serum Antibody Test and Stool Antigen Test for *Helicobacter pylori* Detection: This was performed according to the instructions of the manufacturing company (German-Acon).⁹

Estimation of TGF- β 1 and IL-18 by Enzyme-linked Immunosorbent Assay (ELISA) Protocols: This was performed according to the instructions of the manufacturing company (BTLAB).¹⁰

Statistical Analysis

The common statistical package GraphPad Prism version 7 was used, and the data were summarised using the Mean Stander division format. The degree of association between markers was estimated using correlation coefficients. Mega stat (Version v 10.12) for Excel 2010 was used to calculate descriptive statistics and correlation coefficients.

Results and Discussion

Demographic Study

The current study included 89 samples, which were separated into two groups for further analysis (gastritis patient: 50 (56.18%), and control: 39 (43.82%)). According to the results of the study, the male patients outnumbered the female patients by a margin of 28 (56%) to 22 (44%) for gastritis patients, while males were less than females (15 (38.5%) versus 24 (61.5%)) in the control group as illustrated in Figure 1.




Figure 1. Distribution of Patients and Control According to Gender

H. pylori colonises and thrives in the acidic pH of the stomach. It then enters the stomach's epithelial cell through the mucus layer.¹¹ *H. pylori* needs the urease enzyme to survive in the acidic stomach, since it may neutralise gastric acidity and cause damage to the gastric mucosa via the production of toxins such as CagA and VacA.¹² The relationship between *H. pylori* isolation from gastrointestinal patients and many immunological characteristics was investigated, as was the efficacy of molecular versus serological approaches for the identification of *H. pylori*.

Rapid Diagnostic Test

The result of all 50 patients was tested using the Rapid Diagnostic Test (RDT) to identify *H. pylori* antibody (Ab) and antigen (Ag) in a single step. Table 1 displays the percentages of patients with positive (26, 52%) and negative (24, 48%) Ab test results and positive (20, 40%) and negative (30, 60%) Ag test results.

Table 1. Positive and Negative Results of Stool Antigen and Serum Antibody Test for *H. Pylori*

Method	Tests	Results	n (%)	p Value
Rapid diagnostic test	Ab	Positive	26 (52)	p > 0.05
		Negative	24 (48)	
	Ag	Positive	20 (40)	p > 0.05
		Negative	30 (60)	

The results of the present study showed that rapid diagnostic test helps to identify *H. pylori* infection as shown in Table 1. Positive results for rapid diagnostic tests for *H. pylori* infection have been shown to vary from 63% to 88% across nations.^{13,14} This is because each individual's immune response is unique and the length of time an infection has been present might also have an impact on the outcome.¹⁵ Due to a lack of discrimination between active and latent infections, the test's sensitivity and specificity are reduced and false positives are more likely to occur.¹⁶

Immunological Study

Evaluation of TGF- β 1 in Patients

The present study showed that TGF- β 1 (pg/mL) concentration was higher in the patient group as compared to the control group (556.6 \pm 44.24 pg/mL and 184.7 \pm 12.19 pg/mL, respectively). Significant differences were found between the patient group and control group at p \leq 0.05, as shown in Figure 2.

In this study, researchers found that TGF-1 serum levels were significantly higher in patients as compared to controls. This finding is consistent with that of Serruya and Maor,¹⁷ who discovered a statistically significant rise in TGF-1 serum levels of patients as compared to those of controls.




Figure 1 .Distribution of Patients and Control According to Gender

***: Significant

Treg cell responses in infected patients with gastritis were capable of modulating Th1 and Th17 cell responses that possibly contributed to the persistence of *H. pylori* infection, as shown by the fact that the number of Tregs and the expression of TGF-1 were significantly higher in infected patients who developed gastritis than in control patients.¹⁸

Previous research has revealed that TGF facilitates *H. pylori* attachment to and colonisation of host cells.¹⁹ TGF has been linked to gastritis and autoimmune illnesses that *H. pylori* causes in the stomach.²⁰ Macrophages, lymphocytes, and foam cells are just a few of the cell types that may produce TGF, making it a potentially ubiquitous inflammatory mediator. The degree of *H. pylori*-associated non-metaplastic atrophic gastritis correlates with the level of TGF-1 expression.²¹ *H. pylori* infection is associated with an increase in TGF-1 mRNA expression in human gastric mucosal biopsies, and this effect is positively correlated with the VacA genotype and the grade of chronic inflammation.^{22,23}

Evaluation of IL-18 in Patients

The present study showed that IL-18 (pg/mL) concentration was higher in the patient group as compared to the control group (30.73 ± 2.233 pg/mL and 13.11 ± 0.6768 pg/mL, respectively). Significant differences were observed between the patient group and the control group at $p \leq 0.05$ as shown in Figure 3.

IL-18 is a cytokine that plays an important role in the immune response to *H. pylori* infection, a common cause of gastroenteritis and stomach ulcers. IL-18 is generated by epithelial cells and monocytes/ macrophages in the gastric mucosa, and its levels are associated with the severity of inflammation.²⁴ IL-18 induction by *H. pylori* depends on the virulence factors of the bacteria, such as the cytotoxin-associated gene A protein (CagA) pathogenicity island and Outer Membrane Inflammatory Protein (Oip) which activate different signalling pathways in the host cells.²⁵ *H. pylori* can also induce IL-1 β production in monocytes, which is regulated by the NLRP3 inflammasome. both IL-1 β and IL-18 are members of the IL-1 family of cytokines, which have proinflammatory effects and can modulate Th1/ Th17 responses.²⁶

In summary, *H. pylori* infection is associated with increased levels of IL-18. However, the effect of *H. pylori* infection on IL-18 levels specifically varies depending on the study. Some studies have found that IL-18 levels are higher in *H. pylori*-infected patients than in healthy individuals, while others have found that IL-18 levels in the two groups are similar.

Correlation Between TGF- β 1 and IL-18 Serum Level in Patients with *H. pylori* and Bacterial Infection




Figure 2. Comparative Concentrations of TGF- β 1 Between Study Groups

***: Significant




Figure 4. Correlation between TGF- β 1 and IL-18 Serum Levels

There are several studies that have investigated the correlation between TGF- β 1 and IL-18 serum levels in relation to *H. pylori* and bacterial infections. One such study showed that TNF- α and TGF- β 1 influence IL-18-induced IFN- γ production through the regulation of IL-18 receptor and T-bet expression.²⁷ It is recommended to employ the molecular technique to measure the level of cytokines against pathogens; this technique such as PCR was applied in different topics of the medical field.^{28–39}

In summary, TGF- β 1 and IL-18 are cytokines that play important roles in the immune system, including the regulation of immune responses against bacterial pathogens.

Conclusion

IL-18 and TGF- β 1 levels were elevated in the serum of people with gastritis *H. pylori* infection in this study as compared to the healthy groups. A correlation was found between TGF- β 1 and IL-18 serum levels in relation to *H. pylori* and bacterial infection.

Source of Funding: None

Conflict of Interest: None

References

1. Azer SA, Awosika AO, Akhondi H. Gastritis. 2021 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021 [cited 2023 Jul 21]. Available from: <https://pubmed.ncbi.nlm.nih.gov/31334970/> [PubMed]
2. Hassuna NA, Hussien SS, Abdelhakeem M, Aboalela A, Ahmed E, Abdelrahim SS. 2023. Regulatory B cells (Bregs) in *Helicobacter pylori* chronic infection. *Helicobacter*. 2023;28(2):e12951. [PubMed] [Google Scholar]
3. Soares GA, Moraes FA, Ramos AF, Santiago SB, Germano JN, Fernandes GA, Curado MP, Barbosa MS. 2023. Dietary habits and *Helicobacter pylori* infection: is there an association? *Therap Adv Gastroenterol*. 2023;16:17562848231160620. [PubMed] [Google Scholar]
4. Villar VH, Subotički T, Đikić D, Mitrović-Ajtić O, Simon F, Santibanez JF. Transforming growth factor- β 1 in cancer immunology: opportunities for immunotherapy. *Adv Exp Med Biol*. 2023;1408:309-28. [PubMed] [Google Scholar]
5. Connors J, Joyner D, Mege NJ, Cusimano GM, Bell MR, Marcy J, Taramangalam B, Kim KM, Lin PJ, Tam YK, Weissman D, Kutzler MA, Alameh MG, Haddad EK. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. *Commun Biol*. 2023;6(1):188. [PubMed] [Google Scholar]
6. Wang L, Cao ZM, Zhang LL, Dai XC, Liu ZJ, Zeng YX, Li XY, Wu QJ, Lv WL. *Helicobacter pylori* and autoimmune diseases: involving multiple systems. *Front Immunol*. 2022;13:833424. [PubMed] [Google Scholar]
7. Wautier JL, Wautier MP. Pro-and anti-inflammatory prostaglandins and cytokines in humans: a mini review. *Int J Mol Sci*. 2023;24(11):9647. [PubMed] [Google Scholar]
8. Schröder D, Müller F, Heesen G, Hummers E, Dopfer-Jablonka A, Vahldiek K, Klawonn F, Steffens S, Mikuteit M, Niewolik J, Heinemann S. Feasibility of self-organized blood sample collection in adults for study purposes in a primary care setting. *PLoS One*. 2023;18(5):e0286014. [PubMed] [Google Scholar]
9. Shaaban SI, Talat D, Khatab SA, Nossair MA, Ayoub MA, Ewida RM, Diab MS. An investigative study on the zoonotic potential of *Helicobacter pylori*. *BMC Vet Res*. 2023;19(1):16. [PubMed] [Google Scholar]

10. Elkot SM, Eltayeb TM. Non surgical periodontal treatment effect on Il-17 and Il-18 levels in gingival crevicular fluid of stage III/IV, molar/incisor pattern periodontitis. *Egypt Dent J.* 2023;69(3):1919-25. [Google Scholar]
11. Song Q, Ding X, Liu Y, Liu W, Li J, Wang B, Gu Z. Gastric acid powered micromotors for combined-drug delivery to eradicate *Helicobacter pylori*. *Appl Mater Today.* 2023;31:101779. [Google Scholar]
12. Mohammadzadeh R, Menbari S, Pishdadian A, Farsiani H. *Helicobacter pylori* virulence factors: subversion of host immune system and development of various clinical outcomes. *Expert Rev Mol Med.* 2023;25:e23. [PubMed] [Google Scholar]
13. Al-Badaii F, Bajah K, Ahmed S, Al-Ameri H, Shumaila H, Abbas Z, Saad FA. Prevalence of *Helicobacter pylori* infection and associated risk factors among schoolchildren at Dhamar City, Yemen. *Int J Sci Res Biol Sci.* 2021;8(6):16-22. [Google Scholar]
14. Mouliou DS. Managing viral emerging infectious diseases via current molecular diagnostics in the emergency department: the tricky cases. *Expert Rev Anti Infect Ther.* 2022;20(9):1163-9. [PubMed] [Google Scholar]
15. Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? *Ageing Res Rev.* 2021;71:101422. [PubMed] [Google Scholar]
16. Hussein RA, Al-Ouqaili MT, Majeed YH. Detection of *Helicobacter pylori* infection by invasive and non-invasive techniques in patients with gastrointestinal diseases from Iraq: a validation study. *PLoS One.* 2021;16(8):e0256393. [PubMed] [Google Scholar]
17. Serruya R, Maor Y. Hair growth-promotion effects at the cellular level and antioxidant activity of the plant-based extract Phyllotex™. *Heliyon.* 2021;7(9):e07888. [PubMed] [Google Scholar]
18. Nemattalab M, Shenagari M, Taheri M, Mahjoob M, Chamaki FN, Mojtahedi A, Hasan-Alizadeh E, Ashrafkhani B, Niri NM. Co-expression of interleukin-17A molecular adjuvant and prophylactic *Helicobacter pylori* genetic vaccine could cause sterile immunity in Treg suppressed mice. *Cytokine.* 2020;126:154866. [PubMed] [Google Scholar]
19. Li N, Xie C, Lu NH. Transforming growth factor- β : an important mediator in *Helicobacter pylori*-associated pathogenesis. *Front Cell Infect Microbiol.* 2015;5:77. [PubMed] [Google Scholar]
20. Zeng J, Xie C, Zhang L, Liu X, Chan MT, Wu WK, Chen H. Host cell antimicrobial responses against *Helicobacter pylori* infection: from biological aspects to therapeutic strategies. *Int J Mol Sci.* 2022;23(18):10941. [PubMed] [Google Scholar]
21. Dincă AL, Meliț LE, Mărginean CO. Old and new aspects of *H. pylori*-associated inflammation and gastric cancer. *Children (Basel).* 2022;9(7):1083. [PubMed] [Google Scholar]
22. Kashyap D, Rele S, Bagde PH, Saini V, Chatterjee D, Jain AK, Pandey RK, Jha HC. Comprehensive insight into altered host cell-signaling cascades upon *Helicobacter pylori* and Epstein–Barr virus infections in cancer. *Arch Microbiol.* 2023;205(7):262. [PubMed] [Google Scholar]
23. Fiorani M, Tohumcu E, Del Vecchio LE, Porcari S, Cammarota G, Gasbarrini A, Ianiro G. The influence of *Helicobacter pylori* on human gastric and gut microbiota. *Antibiotics (Basel).* 2023;12(4):765. [PubMed] [Google Scholar]
24. Pachathundikandi SK, Tegtmeier N, Backert S. Masking of typical TLR4 and TLR5 ligands modulates inflammation and resolution by *Helicobacter pylori*. *Trends Microbiol.* 2023;31(9):903-15. [PubMed] [Google Scholar]
25. de Melo FF, Marques HS, Pinheiro SL, Lemos FF, Luz MS, Teixeira KN, Souza CL, Oliveira MV. Influence of *Helicobacter pylori* oncoprotein CagA in gastric cancer: a critical-reflective analysis. *World J Clin Oncol.* 2022;13(11):866-79. [PubMed] [Google Scholar]
26. Giannos P, Prokopoulos K, Isanejad M, Wright HL. Markers of immune dysregulation in response to the ageing gut: insights from aged murine gut microbiota transplants. *BMC Gastroenterol.* 2022;22(1):533. [PubMed] [Google Scholar]
27. Pandith AA, Bhat I, Mansoor S, Koul A, Manzoor U, Anwar I, Mohammad F, Aein QU, Baba SM, Vladulescu C. Cytokine gene polymorphism and cancer risk: a promising tool for individual susceptibility and prognostic implications. In: Caliskan M, Tavsanlı N, editors. *Genetic polymorphisms: new insights.* IntechOpen; 2022. [Google Scholar]
28. Saleh TH, Hashim ST, Malik SN, Al-Rubaii BA. The impact some of nutrients on swarming phenomenon and detection the responsible gene *RsbA* in clinical isolates of *Proteus mirabilis*. *Int J Res Pharm Sci.* 2020;11(1):437-44.
29. Jalil IS, Mohammad SQ, Mohsen AK, Al-Rubaii BA. Inhibitory activity of *Mentha spicata* oils on biofilms of *Proteus mirabilis* isolated from burns. *Biomedicine.* 2023;43(2):748-52. [Google Scholar]
30. Mohsin MR, Al-Rubaii BA. Bacterial growth and antibiotic sensitivity of *Proteus mirabilis* treated with anti-inflammatory and painkiller drugs. *Biomedicine.* 2023;43(2):728-34. [Google Scholar]
31. Rasoul LM, Marhoon AA, Albaayit SF, Ali RW, Saleh TH, Al-Rubaii BA. Cytotoxic effect of cloned EGFP gene on NCI-H727 cell line via genetically engineered gene transfer system. *Biomedicine.* 2022;42(5):938-42.

- [Google Scholar]
32. Bresam S, Al-Jumaily RM, Karim GF, Al-Rubaii BA. Polymorphism in SNP rs972283 of the KLF14 gene and genetic disposition to peptic ulcer. *Biomedicine*. 2023;43(1):216-20. [Google Scholar]
 33. Ismael MK, Qaddoori YB, Shaban MN, AL-Rubaii BA. The immunohistochemical staining of Vimentin and E-Cadherin in bladder cancer patients infected with hepatitis C virus. *J Pure Appl Microbiol*. 2023;17(2):1009-16. [Google Scholar]
 34. Bresam S, Alhumairi RM, Hade IM, Al-Rubaii BA. Genetic mutation rs972283 of the KLF14 gene and the incidence of gastric cancer. *Biomedicine*. 2023;43(4):1256-60. [Google Scholar]
 35. Al-Saadi HK, Awad HA, Saltan ZS, Hasoon BA, Abdulwahab AI, Al-Azawi KF, Al-Rubaii BA. Antioxidant and antibacterial activities of *Allium sativum* ethanol extract and silver nanoparticles. *Trop J Nat Prod Res*. 2023;7(6):3105-10. [Google Scholar]
 36. Hamoode RH, Alkubaisy SA, Sattar DA, Hamzah SS, Saleh TH, Al-Rubaii BA. Detection of anti-testicular antibodies among infertile males using indirect immunofluorescent technique. *Biomedicine*. 2022;42(5):978-82. [Google Scholar]
 37. Rasoul LM, Allami RH, Alshibib AL, Al-Rubaii BA, Sale TH. Expression and cytotoxic effect of recombinant Newcastle Disease Virus (rNDV) vector expressing enhanced green fluorescent gene in JHH5 cell line. *Biomedicine*. 2023;43(1):205-9. [Google Scholar]
 38. Jawad NK, Numan AT, Ahmed AG, Saleh TH, Al-Rubaii BA. IL-38 gene expression: a new player in Graves' ophthalmopathy patients in Iraq. *Biomedicine*. 2023;43(1):210-5. [Google Scholar]
 39. Husain AG, Alrubaii BA. Molecular detection and expression of virulence factor encoding genes of *Pseudomonas aeruginosa* isolated from clinical samples. *Biomedicine*. 2023;43(5):1514-9. [Google Scholar]